Trial Outcomes & Findings for Patient Satisfaction With Propofol for Out Patient Colonoscopy (NCT NCT02937506)
NCT ID: NCT02937506
Last Updated: 2017-12-26
Results Overview
Satisfaction assessed using self-developed questionnaire.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
600 participants
Primary outcome timeframe
Patient satisfaction was assessed the day of the procedure.
Results posted on
2017-12-26
Participant Flow
Participant milestones
| Measure |
Propofol
Patients in the treatment arm will be given propofol only when having a colonoscopy.
Propofol: The intervention is to use propofol as anesthesia during a colonoscopy.
|
Fentanyl Plus Midazolam Only
Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
Fentanyl Plus Midazolam: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
|
|---|---|---|
|
Overall Study
STARTED
|
300
|
300
|
|
Overall Study
COMPLETED
|
300
|
300
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Patient Satisfaction With Propofol for Out Patient Colonoscopy
Baseline characteristics by cohort
| Measure |
Propofol
n=300 Participants
Patients in the treatment arm will be given propofol only when having a colonoscopy.
Propofol: The intervention is to use propofol as anesthesia during a colonoscopy.
|
Fentanyl Plus Midazolam Only
n=300 Participants
Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
Fentanyl Plus Midazolam: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
|
Total
n=600 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
61.4 Years
STANDARD_DEVIATION 9.8 • n=5 Participants
|
61.0 Years
STANDARD_DEVIATION 9.4 • n=7 Participants
|
61.2 Years
STANDARD_DEVIATION 9.6 • n=5 Participants
|
|
Sex: Female, Male
Female
|
138 Participants
n=5 Participants
|
147 Participants
n=7 Participants
|
285 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
162 Participants
n=5 Participants
|
153 Participants
n=7 Participants
|
315 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Patient satisfaction was assessed the day of the procedure.Population: Same as enrolled.
Satisfaction assessed using self-developed questionnaire.
Outcome measures
| Measure |
Propofol
n=300 Participants
Patients in the treatment arm will be given propofol only when having a colonoscopy.
Propofol: The intervention is to use propofol as anesthesia during a colonoscopy.
|
Fentanyl Plus Midazolam Only
n=300 Participants
Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
Fentanyl Plus Midazolam: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
|
|---|---|---|
|
Patient Satisfaction
Very Satisfied
|
259 Participants
|
222 Participants
|
|
Patient Satisfaction
Satisfied
|
37 Participants
|
66 Participants
|
|
Patient Satisfaction
Neutral/Less than satisfied
|
4 Participants
|
12 Participants
|
Adverse Events
Propofol
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Fentanyl Plus Midazolam Only
Serious events: 0 serious events
Other events: 17 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Propofol
n=300 participants at risk
Patients in the treatment arm will be given propofol only when having a colonoscopy.
Propofol: The intervention is to use propofol as anesthesia during a colonoscopy.
|
Fentanyl Plus Midazolam Only
n=300 participants at risk
Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
Fentanyl Plus Midazolam: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
|
|---|---|---|
|
Gastrointestinal disorders
Nausea/Emesis
|
2.3%
7/300 • Number of events 300
|
5.7%
17/300 • Number of events 300
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place